Stay updated with breaking news from Cingulate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cingulate (NASDAQ:CING – Get Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.08), reports. Cingulate Price Performance Shares of NASDAQ:CING opened at $1.02 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.12 […]
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for...
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial ProgramKANSAS CITY, Kan., May 03, 2023 -- Cingulate Inc. ,... | May 3, 2023
Cingulate Announces Successful Transfer of CTx-1301 Proprietary PTR™ Manufacturing Processes to Societal CDMO Scalable Supply of CTx-1301 Ready to be... | May 3, 2023
KANSAS CITY, Kan., April 14, 2023 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a... | April 14, 2023